Key questions for perioperative chemotherapy in resectable lung cancer: not pre vs post, but who and what?

Oncology (Williston Park). 2009 May;23(6):527, 532.

Authors

Heather A Wakelee¹, Robert Merritt, Christelle Clément-Duchêne

Affiliation

¹ Stanford Cancer Center, Stanford, California, USA.

PMID: 19544694

No abstract available

Publication types

Comment

MeSH terms

Antigens, Neoplasm / immunology
Cancer Vaccines
Carcinoma, Non-Small-Cell Lung / mortality
Carcinoma, Non-Small-Cell Lung / pathology
Carcinoma, Non-Small-Cell Lung / therapy*
Chemotherapy, Adjuvant
ErbB Receptors / antagonists & inhibitors
Erlotinib Hydrochloride
Humans
Lung Neoplasms / mortality
Lung Neoplasms / pathology
Lung Neoplasms / therapy*
Neoadjuvant Therapy
Neoplasm Proteins / immunology
Patient Selection
Protein Kinase Inhibitors / therapeutic use
Quinazolines / therapeutic use
Randomized Controlled Trials as Topic

Substances

Antigens, Neoplasm
Cancer Vaccines
MAGEA3 protein, human
Neoplasm Proteins
Protein Kinase Inhibitors
Quinazolines
Erlotinib Hydrochloride
ErbB Receptors